FDA's accelerated approval pathway needs stronger transparency, evidence standards: ICER

The FDA should strengthen the evidence required for drug approvals under its accelerated pathway, and increase the transparency surrounding those regulatory decisions, too, according to a report from a prominent industry and government watchdog.